Log In Sign up
The largest database of trusted experimental protocols

Ly2606368

Manufactured by MedChemExpress
Visit Supplier
Sourced in United States

LY2606368 is a laboratory equipment product offered by MedChemExpress. It functions as a tool for chemical synthesis and analysis. The core purpose of this product is to facilitate various experimental procedures in a research or laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

P akt ser473, by Cell Signaling Technology (1 mentions) Cisplatin, by Merck Group (1 mentions) Gapdh, by Bioworld Technology (1 mentions) Azd7762, by Selleck Chemicals (1 mentions) Gdc 0941, by Cayman Chemical (1 mentions) Pf 477736, by Merck Group (1 mentions) P chk1 ser296, by Cell Signaling Technology (1 mentions) Byl719, by Novartis (1 mentions) Otx 015, by MedChemExpress (1 mentions)

2 protocols using ly2606368

1

Investigating CHK1 and PI3K Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
The CHK1 inhibitors PF477736 (Sigma-Aldrich, USA), AZD7762 (Selleck Chemicals, CA, USA), and LY2606368 (MedChem Express, USA); as well as the PI3K inhibitors GDC0941 (Cayman Chemical, USA) and GSK1059615 (Cayman Chemical, USA) were used. The PI3K inhibitor BYL719 was kindly provided by Novartis Pharma AG (Basal, Switzerland). Cisplatin was purchased from Sigma-Aldrich. Antibodies against the following molecules were used for immunoblotting: CHK1, p-CHK1-Ser296, AKT, p-AKT-Ser473 (Cell Signaling Technology), and GAPDH (Bioworld, USA).
Yang C.Y., Liu C.R., Chang I.Y., OuYang C.N., Hsieh C.H., Huang Y.L., Wang C.I., Jan F.W., Wang W.L., Tsai T.L., Liu H., Tseng C.P., Chang Y.S., Wu C.C, & Chang K.P. (2020). Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. Cancers, 12(7), 1726.
+ Open protocol
+ Expand
2

Solvent Preparation for In Vitro and In Vivo Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
OTX-015 and LY2606368 (MedChem Express, Monmouth Junction, NJ, USA) and SRA737 (Chemietek, Indianapolis, IN, USA) were dissolved in 100% dimethyl sulfoxide (DMSO) for in vitro studies. The final concentration of DMSO for all drugs in all cell cultures was ≤0.1%. OTX-015 and SRA737 were dissolved in 10% DMSO, 20% PEG400, 5% Tween 80, and 65% water for the in-vivo studies.
Pandya P.H., Cheng L., Saadatzadeh M.R., Bijangi-Vishehsaraei K., Tang S., Sinn A.L., Trowbridge M.A., Coy K.L., Bailey B.J., Young C.N., Ding J., Dobrota E.A., Dyer S., Elmi A., Thompson Q., Barghi F., Shultz J., Albright E.A., Shannon H.E., Murray M.E., Marshall M.S., Ferguson M.J., Bertrand T.E., Wurtz L.D., Batra S., Li L., Renbarger J.L, & Pollok K.E. (2020). Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma. Cancers, 12(9), 2426.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!